101. DNA and histone methylation in gastric carcinogenesis.
- Author
-
Calcagno DQ, Gigek CO, Chen ES, Burbano RR, and Smith Mde A
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Cell Transformation, Neoplastic drug effects, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Gene Expression Regulation, Neoplastic, Humans, Molecular Targeted Therapy, Stomach Neoplasms drug therapy, Stomach Neoplasms metabolism, Stomach Neoplasms pathology, Cell Transformation, Neoplastic genetics, DNA Methylation drug effects, Epigenesis, Genetic drug effects, Histones metabolism, Stomach Neoplasms genetics
- Abstract
Epigenetic alterations contribute significantly to the development and progression of gastric cancer, one of the leading causes of cancer death worldwide. Epigenetics refers to the number of modifications of the chromatin structure that affect gene expression without altering the primary sequence of DNA, and these changes lead to transcriptional activation or silencing of the gene. Over the years, the study of epigenetic processes has increased, and novel therapeutic approaches that target DNA methylation and histone modifications have emerged. A greater understanding of epigenetics and the therapeutic potential of manipulating these processes is necessary for gastric cancer treatment. Here, we review recent research on the effects of aberrant DNA and histone methylation on the onset and progression of gastric tumors and the development of compounds that target enzymes that regulate the epigenome.
- Published
- 2013
- Full Text
- View/download PDF